Wednesday, 31 July 2019

Fibroadenoma of Breast & different diagnose tests to arrive at a definitive diagnosis diagnose Breast lump.


fibroadenoma is a very common benign  breast condition. The most common symptom is a lump in the breast which during a clinical breast exam, you or  doctor will check both breasts for lumps and other problems. Some fibroadenomas are too small to feel, so they can only be discovered in imaging tests. The overall diagnostic efficacy of these three modalities—namely, A) manual breast examination, B)  imaging and C)  cytology is approximately 70% to 80%, but they provide a 95% (±2% SD) accurate differentiation between a benign and a malignant lesion. A follow-up period of 1 to 3 years after fibroadenoma is diagnosed and breast cancer is excluded using the three modalities can enhance the accuracy of the diagnosis. If you have a lump that can be felt (palpable), it will be wise to go ahead with some tests and those tets depends /or procedures, will depend on her age and the characteristics of the lump.
What is etiology ?  OBJECTIVE
To identify from the literature and clinical experience a rational approach to management of fibroadenomas of the breast.
METHOD
Recent literature on detection, diagnosis, and natural history of fibroadenomas was reviewed. Experience with over 4,000 women evaluated in the breast clinic at the Tel- Aviv Medical Center contributed to the management strategies suggested by review of the literature.
RESULTS
Fibroadenomas of the breast are common, accounting for 50% of all breast biopsies performed. Physical examination, sonography, and fine needle aspiration are effective in distinguishing fibroadenomas from breast cancer. Transformation from fibroadenoma to cancer is rare; regression or resolution is frequent, supporting conservative approaches to follow-up and management.
CONCLUSION
Age-based algorithms that allow for conservative management and that limit excision to patients whose fibroadenomas fail to regress are presented.
Keywords: fibroadenoma, breast neoplasms, women
Fibroadenomas are common benign lesions of the breast that usually present as a single breast mass in young women. They are assumed to be aberrations of normal breast development or the product of hyperplasic processes, rather than true neoplasms.
How to examine Breasts at Exam Hall / or your private clinic??  If male candidate ask ward Nurse to be present and be polite,& courteous to woman concerned, Show & practice as U practice how best to palpate  thyroid, Axillary glands!!
Dilemma & Dilemma; To do or not to do: After a clinical diag of Fibroadenoma you now have two options like Breast sonography & FNAC,I leave it to members,-The clinician often faces the dilemma whether to remove the mass or to monitor it by means of periodic follow-up examinations.
Adv of  surgical removal:-Although removal of these lesions is a definitive solution, But disadvantages of surgery: surgery may involve 1) unnecessary excisions of benign lesions and2) unbecoming cosmesis. Moreover, a policy of conducting surgery on all patients with fibroadenomas would place an 3) enormous burden on health care systems.

Then  whom to vote for ?? What is in your back of mind?? Thinking:1:- Cancer probality in near future. Or no cancer?? That lurks in one’s mind,. A balanced and rational approach to the management of a   fibroadenoma of the breast needs to address the crucial questions about its association with breast cancer, especially whether or not it is a marker of increased risk of breast malignancy. Another consideration to be weighed is that a Thinking: 2 :-A  substantial percentage of these lesions undergo spontaneous regression. Herein, based on our review of the current data on fibroadenomas of the breast and our experience, we propose practical algorithms for their management.
What is the prevalence.  More common in young women. Fibroadenomas usually form during menarche (15 –25 years of age), a time at which lobular structures are added to the ductal system of the breast There are no clear-cut data on the incidence of fibroadenomas in the general population. In one study, the rate of occurrence of fibroadenomas in women who were examined in breast clinics was 7% to 13%  while it was 9% in another study of autopsies. Fibroadenomas comprise about  A) 50% of all breast biopsies, and this rate rises to B)  75% for biopsies in women under the age of 20 years. Fibroadenomas are more frequent among women in  C) higher socioeconomic classes  and in dark-skinned populations.

Can I take OCP:_Yes, no restrictions in presence Fibroadenoma. The age of menarche, the age of menopause, and hormonal therapy, including oral contraceptives, were shown not to alter the risk of these lesions.,

Which factors discourages development of fibroadenoma?? body mass index and the number of full-term pregnancies were found to have a negative correlation with the risk of fibroadenomas., Moreover, consumption of large quantities of vitamin C and  surprisingly cigarette smoking were found to be associated with reduced risk of a fibroadenoma.
No genetics factors are known to alter the risk of fibroadenoma. However, a family history of breast cancer in first-degree relatives was reported by some investigators to be related with increased risk of developing these tumors.
At What  age this initiates??   Fibroadenomas usually form during menarche (a time at which lobular structures are added to the ductal system of the breast . Hyperplasic lobules are common at that time, and may be regarded as a normal phase of breast development.  Hyperplasic lobules were shown to be Histologically identical with fibroadenomas.  .Analyses of the cellular components of fibroadenomas by means of polymerase chain reaction demonstrated that both the stromal and the epithelial cells are polyclonal supporting the theory that fibroadenomas are hyperplasic lesions associated with aberration of the normal maturation of the breast, rather than true neoplasms.
An external file that holds a picture, illustration, etc.
Object name is jgi_188_f1.jpg

1
Histologic section of a fibroadenoma (hematoxylin-eosin staining, × 40). The cellular fibroblastic stroma, which resembles interlobular stroma, encloses glandular and cystic spaces lined by epithelium. Round and oval gland spaces, lined by either single or multiple cell layers, are present in other areas. The stroma in the connective tissue appears to have undergone a more active proliferation with compression on the gland spaces. The pattern of stromal growth in a fibroadenoma depends on its epithelial component: stromal mitotic activity was found to be higher near this component.1 Fibroadenomas are stimulated by estrogen and progesterone, and by lactation during pregnancy, and they undergo atrophic changes in menopause. Some fibroadenomas have receptors and respond to growth hormone and epidermal growth factor.
How a woman present with Fibroadenoma??  A fibroadenoma is most often detected incidentally during a medical examination or during self examination, usually as a discrete solitary breast mass of 1 to 2 cm Although they can be located anywhere in the breast, the majority are situated in the upper outer quadrant A fibroadenoma is usually smooth, mobile, contender, and rubbery in consistency .  Several other breast lesions have similar characteristics, and physical examinations provided an accurate diagnosis in only one half to two thirds of cases studied. However, most of the masses that are erroneously diagnosed by palpation as fibroadenomas are found on histologic examination to be another benign form of breast disease,  such as cystic fibrosis.

How useful Breast sonography??  Breast sonography is often used for the diagnosis of fibroadenomas. The sonographic criteria that support the diagnosis of a fibroadenoma are a round or oval solid mass with a smooth contour and weak internal echoes in a uniform distribution and intermediate acoustic attenuation  ,This imaging technique is very useful for differentiating between solid and cystic lesions. However, attempts to correlate between the sonographic features of solid masses compatible with fibroadenomas and pathologic findings were disappointing.  There is some overlap in the sonographic criteria for fibroadenomas and for breast cancer  and approximately 25% of fibroadenomas appear with irregular margins, which may imply that the lesions are malignant.  Also, only 82% of biopsy-proven fibroadenomas were visualized by sonography in one study..

An external file that holds a picture, illustration, etc.
Object name is jgi_188_f2.jpg

Treatment: A) Follow up:-In many cases, fibroadenomas require no treatment. However, some women choose surgical removal for their peace of mind. If physician is reasonable certain that  breast lump is a fibroadenoma — based on the results of the A) clinical breast exam & Axillary gland palpitation, B)  imaging test and C) FNAC:-biopsy — then follow up may be advised without lumpectomy..
Points against surgery?? Because:
·         Surgery can distort the shape and texture of the breast
·         Fibroadenomas sometimes shrink or disappear on their own
·         The breast has multiple fibroadenomas that appear to be stable — no changes in size on an ultrasound compared to an earlier ultrasound
If one is advised not to have surgery, it's important to monitor the fibroadenoma under regular  follow-up visits preferably under the supervision of a dedicated  breast clinic if available  nearby .
Rpt breast ultrasounds to detect changes in the appearance or size of the lump may be necessary .
Surgery: What kind??
It may be necessary to remove the fibroadenoma if lump is big; the fibroadenoma is extremely large, gets bigger or causes symptoms.
& consultant after reviewing all the three reports, taken together —1)  the clinical breast exam, 2) an imaging test or 3) FNAC is abnormal or if Procedures to remove a fibroadenoma include:

 Can left out Fibroadenoma turn out to be cancer??
This is an imp topic that every woman & surgeon would like to know about it?? The associations of fibroadenomas with breast cancer must address two main questions: whether or not a fibroadenoma is a marker for increased risk of breast cancer, and whether or not breast cancer can evolve from the epithelial component of a fibroadenoma. The first issue was originally assessed in several retrospective studies, which demonstrated a 1.3 to 2.1 increased risk of breast cancer in women with fibroadenomas compared with the general population. The elevated risk was persistent, and did not decrease with time. A more recent study designed to delineate the possible correlation between the histologic features of the fibroadenomas and the risk for subsequent breast cancer used the term “complex fibroadenoma.”

 Malignant transformations in the epithelial components of fibroadenomas are generally considered rare. The incidence of a carcinoma evolving within a fibroadenoma was reported to be 0.002% to 0.0125%.,, About 50% of these tumors were lobular carcinoma in situ (LCIS), 20% were infiltrating lobular carcinoma, 20% were ductal carcinoma in situ (DCIS), and the remaining 10% were infiltrating ductal carcinoma. The clinical, sonographic and mammographic findings are usually similar to those of benign fibroadenomas, and the malignant changes are often noted only when the fibroadenoma is excised.
Who are more prone to Ca ?? Fibroadenomas having the histologic characteristic of being A) more than 3 mm in diameter, or B) with elements of sclerosing adenosis, epithelial calcifications, or C) papillary apocrine metaplasia, which were associated with a 3.1 elevated risk of breast cancer. D) Proliferative changes in the parenchyma adjacent to the fibroadenoma were related to a further increase of the risk to 3.88. E) The relative risk for women with a familial history of breast cancer and complex fibroadenoma was 3.72, compared with control women with a family history of breast cancer without fibroadenoma. In these studies, women with noncomplex fibroadenomas and no family history of breast cancer were not at a greater risk of breast cancer.

Breast implant-Breast transplant-Augmentenation mammoplasty


Macromastia (Increased size of the breasts) &  How useful is Breast implant before uterine implant for small breasts?? Discuss before the plastic surgery of breast is contemplated;; Macromastia (Increased size of the breasts), scope of breast reduction can produce dramatic relief in well selected patients &The psychological problem related to asymmetry of breasts:  : This may be a challenges of adolescence when coupled with one sided -macromastia can be responsible for a host of physical  problems including: 1) chronic pain in the breasts,  shoulders and in the neck 2) recurring skin rashes beneath the breasts .and even numbers in  the arms and hands. There is the physical and emotional difficulties of macromastia can prove very difficult for some young women to overcome. Although surgical solutions are not appropriate for every young woman self conscious about breast size breast reduction can produce dramatic relief in well selected patients. Young women must certainly be made to understand the lifelong changes that a choice for surgery can  however causes some pain, ugly scar if get infected and most importantly feeding problem to neonate& infant.  Among the permanent consequences of surgery are scarring the potential for altered nipple sensation and the possible loss of breast feeding capacity. Young patients must be made to confront these issues in a particularly sober way before breast reduction can be seriously entertained.
Although recent controversies have focused public attention upon breast implants and patients seeking breast enlargement a large number of women continue to quietly suffer the discomforts of large breast size . None among this group present the plastic surgeon with a more compelling challenge than do teens and young women. Exaggerated breast development or what doctors call “macromastia” can be responsible for a host of physical problems including chronic pain in the breasts shoulders and neck recurring skin rashes beneath the breasts and even numbness in the arms and hands.
The challenges of adolescence when coupled with the physical and emotional difficulties of macromastia can prove very difficult for some young women to overcome. Although surgical solutions are not appropriate for every young woman self conscious about breast size breast reduction can produce dramatic relief in well selected patients. Young women must certainly be made to understand the lifelong changes that a choice for surgery can mean however . Among  the permanent consequences of surgery are scarring.
Breast asymmetry : A small degree of asymmetry between the breasts is quite normal when differences in volume or shape lead to problems of physical comfort or difficulty in dress surgical intervention may be warranted. This may also be true  in circumstances where asymmetry makes the woman self conscious and ill at ease in intimate situations. Not surprisingly the surgical techniques employed will vary considerably depending upon the nature of the problem.







Friday, 26 July 2019

Oral contraceptive uses -Tips of selecting most appropriate OCP.


Tips in choosing   the best OC formulation .  How to select the most appropriate an OCP  formulation ??
What to take into account?? A) It is   generally recommended to use   the lowest effective  dose.
B)  Age of the woman(the contraceptive sekers) :-As women age   there are different   issues  that affect  hwer metabolic profile which includes lipid, LFT status.
 . Because  of the higher   potency of EE    , OCs   containing   35 ug EE are  similar  to the 50 ug  OCs   containing menstranol .
New  start  Healthy   patients
Adolescents : 20    ug EE OCs  , the  lowest dose 20 ug    EE (except Minesse which contain 15 mcg) in adolescents may  be  associated    with BTB ( a lack of bleeding    control )-  a leading   cause of  discontinuation   . In this  population  starting with a 25(not available in our country)    or 30 ug  EE OC may be associated   with better   bleeding control   and ultimately  better compliance. However the biphasic or monophonic   20 ug OCs  with shortened  pill free   intervals are associated  with improved  bleeding    control  and may    be a good   option  to consider. Indicatiosn of OCP in adolescents?? It is prescribed for  many    non  contraceptive    benefits :
I Dysmenorrhea   2) bleeding    control  . All OC  brands   show benefit   25 and 30 ug  OCs  may have better  bleeding  control than  traditional 20 ug OCs with a 7 day pill free  interval. Reviews have   shown   that OCs   with levonorgestrel (androgenic progesterone) have good  bleeding control.
3) Acne   : Choice is nonandrogenic prog liked desogestrel:-androgenic problems. All OCs   brands   show benefit  but  If  symptoms are  severe  or continue to be a problem  while on an OC   switch   OC with   formulation  containing  a low   androgenic  progestin desogestrel , ortho Tri  Cyclen ( abroad) is approved   by the Food  and Drug   administration to treat acne   vulgaris.
4) If engaged regularly in illegal/illicit sex(married /unmarried) i/e  users    with at risk of STD or HIV   exposure   need additional protection and   should  use  condoms and OCs .
Take home meassage:-Don’t prescribe low dose formulation which may cause BTB (an unacceptable side effects for teen agers).:_Early   reproductive  first choice : :-Don’t prescribe 20 ,25  ug EE OCPs  in   young women as these brands  may  have increased bleeding problems on 20 ug  OCs  with a  traditional    7 day pill free  interval   a 25 ug  EE OC may result in better bleeding  control Use of  a levonorgestrel containing pill is  associated   with  good  bleeding   control.
Dysmenorrhea    bleeding  control   all OC  brands show  benefit 25 and 30 ug  OCs   better  than   some of the 20 ug  OCs   Reviews  have shown  levonorgestrel  containing   OCs    to have good   bleeding  control
PMS   PMDD or fluid   retention  all OCs  may show  benefit. The  progestin DRSP is a derivative of   spironolactone  and has some diuretic effect . Selection   of an OC with   DRSP  is a good choice for  users  with significant   complaints   of PMS  PMDD  or fluid  retention.
Acne    androgenic problems all OCs  show benefit Consider low androgenic    progestin OCs    if severe or if nonresponsive  to other  OCs   Ortho  Tri cyclen is FDA   approved  to treat   acne vulgaris.
Late    reproductive   first choice : 20-25 ug EE OCs 
Menorrhagia : all  OCs  show    benefit ?If   menorrhagia is a problem while on an OC switch  to OC with  levonorgestrel  or one with    lower EE  dose. Switching to pill with  higher   progestin   to estrogen    ratio results   in less endometrial  stimulation    and may result   in less menstrual   bleeding
Bleeding  problems all Cos   show benefit . If  midcycle  bleeding and spotting   is a problem  while on OC  consider switching to an CO with stronger     progestin such as one  with levonorgestrel or consider   switching  to a higher EE dose  OC Estrogen increases   endometrial    growth and may  improve    bleeding control In   some instances  switching to   a   lower EE done   OC may be   effective   because   it lowers   endometrial  stimulation  which results    in less endometrial     tissue and less bleeding.
Fibroids or endometriosis   all OCs may  show benefit  consider a stronger   progestin OC  such  as one with levonorgestrel  or OC   with as low   a  dose of  EE as  possible.
Significant   menstrual related    problems  consider  a low dose   21 day extended  cycle or continuous OC.
Obesity   for heavier women   consideration of 30  to 35 ug pill extended  use OC or   vaginal  ring   . Using   more than  35 ug OCs may  increase   the risk of venous   thrombo embolisms and  a risk  benefit   ratio should  be considered . As a user get older risk of thrombosis  may increase   and fecundity decreases     therefore   using a low  EE dose OC may be considered . Women   over 35   with long standing obesity   are good candidates for progestin only methods    barriers  IUDs or tubal   sterilization.


Perimenopausal or women over  35 years old  who  are healthy  non hypertensive  nonsmokers  first choice is 20 ug Cos Women  in this age group   with longstanding obesity hypertension   cigarette  smoking  known   or suspected   vascular   disease or diabetes  may consider   progestin only methods  barriers    IUDs or tubal  sterilization.
Perimenopausal symptoms   during  pill free interval  consider   switching  to CO with   shortended  pill   free interval   with EE 20 ug  /150 ug  DSG  for 21 days   , 5days   of 10 ug EE and only  2 days   hormone free   interval or  the new 20 ug OC  containing  3 mg DRSP   with a 4 day hormone free interval

The   amount and potency   of either  the particular  estrogen  or progestin  component   in an OC an d the balance    between the particular     estrogen  and progestin is associated with hormonal side effects as listed . Management   of these problems    generally involves  changing    to an OCP  with a different estrogen   to progestin  balance.
Consider   switching to another OC if   current OC is associated with :
Breakthrough    bleeding   heavy  menses irregular     bothersome  or heavy  bleeding   that continues after 2 months of use    consider OC  with levonorgestrel or   lower EE or  progestin ration pill.
Amenorrhea for two cycles after negative pregnancy   test switch  to OC with   higher EE to  progestin ratio
Acne is exacerbated on OC  switch    to OC with  Norgestimate DSG or DRSP    ortho Tri Cyclenis  FDA    approved to treat  acne vulgaris.
Minor   estrogen     related   side effects  that continue  after 2 months switch  to OC   with lower  EE dose   consider  20 ug EE OC .
Nausea or vomiting Switch   to OC  with lower EE   
Headaches : Stop OCS   immediately  if there are concomitant  localizing  signs auras  blurred  vision weakness or numbness or if the users  is experiencing   a worsening of migratines  
Check  blood pressure
If blood   pressure   normal   headaches  are simple and there are none of the  symptoms above   consider  switching to 20 ug EE OC or progestin only method.
Decreased libido there is a dose dependent  suppression of endogenous  testosterone production by OCs . Additionally estrogen   dominant   pills increase   sex hormone  binding  globulin that binds up endogenous androgens   switching to OC with     20 ug EE or to a progestin  only  OC may result in  more normal   free testosterone levels  and less negative impact  on libido.
Melasma : switch  to  progestin  only OCP  or consider one with  20 ug EE
Mood    swings   to 20 to 25 ug OC  consider  OC with a different  progestin  from current OC consider   DRSP  Norgestimate   or DSG  consider   extended cycle or   continuous  OC.
Weight   gain : Currently   available low dose OCs  are generally   not associated  with   a weight    gain consider   switching to 20- 25f ug EE OC if fluid retention  is problem use an OC containing  DRSP  .

Although  OCs   are safe in healthy normotensive women there  are important   contraindications to their sue and it is important to identify certain risk factors Additionally OCs  are associated with many  non contraceptive      benefits   and the  identification of conditions that may  be improved  with OC  use is also   important.
Pertinent gynecological  issues
Menstrual cycle   irregularities heavy  bleeding anemia
Leiomyomata  uterus previous  surgery 
Polycystic ovary syndrome   recurrent  ovarian cysts
 Dysmenorrhea  pelvic  pain
  Sexual   history exposure   to HIV
Current  and future   childbearing  plans
Androgen   excess  acne hirsutism alopecia
Premenstrual syndrome
Demographics
Age  gravity   parity marital status  occupation
Medications
Good   data  stating that certain  drugs  accelerate  the biotransformation of steroids  in OCs    and concomitant use may make OCs  less effective
Rifampin   sulfonamides   cyclophosphamide barbiturates   certain antiepileptics , butazolindin
St John ‘s Wort
Data    less convincing  for certain   antibiotics   fulconazole 
Low dose    long  term antibiotic     use for acne   appears to be compatible with   oc use
Product   labeling suggests that women taing  potassium sparing diuretics angiotensin converting enzyme   inhibitors  angiotensin II receptor    antagonists chronic    daily use   of nonsteoidal anti  inflammatory   drugs    should   consult  their health  care provider  to check  if a drospirenone   containing   OC is   right for them. Under   these conditions  serum potassium levels   should be checked   during the first  months . Clinical  studies  have reported   minimal incidence   of problems  in women    on these  medications who also take  a  DRSP  containing OC  
Potassium sparing drugs : Women who are ACE  inhibitors  potassium sparing  diuretics heparin angiotensin II receptor  inhibitors aldosterone antagonists or  daily  NSAIDs    should be monitored   for potassium before   and during   use of DRSP   containing  OCs. Multiple  studies  demonstrate safety   of DRSP  containing  pills in for patients  on these medications.


Valvular heart disease this   thrombogenic   complications
Pulmonary hypertension subacute   bacterial endocarditis or atrial fibrillation  
Known   or suspected vascular disease 
Cerebro vascular  or coronary artery  disease  history  of   stroke
Myocardial    infarction known   atheroscelerosis
Diabetes with vascular disease   including retinopathy  or nephropathy
Diabetes  for more  than 20 years
Hypertension
WHO  medical  criteria   classify controlled    adequately  evaluated hypertension  as category     3 the risks generally outweigh  the benefit
Multiple risk factors for   atheroscelerosis  
Personal   history  of thrombosis    or high risk for thrombosis
Thromboembolism   thrombophlebitis deep  vein thrombosis
Polycythemia vera
K own or suspected   inherited  clotting disorder   
Cigarette  smoking in women older than 35
Cancer    of the breast
Any current  estrogen   dependent   neoplasia
Known  or suspected pregnancy
Migraine headaches   with localizing  neurological signs  including scotomata at  any age .
Migraine  without  aura over   age 35
Worsening migraines  during use of  OC .
Acute  or  chronic  lives disease
Active   viral hepatitis  abnormal liver  functions severe  cirrhosis
Benign  hepatic  adenomas / liver   carcinoma
Prolonged immunobilization major surgery
Hypersensitivity to any component of the pill
  History  of  Oc   induced cholestatic   jaundice   or current  symptomatic  gall bladder  disease   treated  medically
Mild   compensated cirrhosia
Postpartum less than  21 days or less  than  6 months  if primarily breastfeeding
Cigarette smoking of less than  15  cigarettes  per day in women 35 years or older or older .
History    of hypertension   in which blood pressured cannot be   monitored    or moderately   elevated systolic blood  pressure   140-159   mmHg   or diastolic    blood pressure  90-99 mmHg
Hypertrigltyceridemia  known   hyperlipidemias 
Migraine without  aura  over 35 years of age
Previous    breast cancer but no evidence  of current  disease for 5 years.,
Certain antibiotics   or anticonvulsants


 Unexplained    vaginal bleeding before   evaluation 
Undiagnosed breast  mass
Varicose veins
Migraine    headaches  without localizing neurological    signs  or aura  more than   35  years .
Non  migrainous  headaches mild or severe  during use.
Cigarette   smoking by women   younger  than age 35 
Age  over 40
Prolactin secretion  pituitary  microadenoma
Valvular heart  disease  uncomplicated
Unexplained amenorrhea after evaluation
Diabetes  with no vascular    disease  in women
Under   35 years of  age and less  than 20 years duration of diabetes
Surgery   without   prolonged  immobilization
Known   hyperlipidemias   with  no other   risk factors  for cardiovascular   disease.
On  antiretinoviral   therapy 
On  Griseofulviin
Obesity   body mass index 30 kg / m or more
Non   migrainous mild  or  sever headache
Cervical   cancer awaiting   treatment
Cervical   intraepithelial neoplasia
Sickle   cell disease  or trait.
Symptomatic   gall bladder   disease treated with cholecytectomy or asymptomatic
Gall bladder disease or history  of pregnancy     induced cholestatic jaundice  
History   of pregnancy   induced hypertension 
Family  history  in first  degree relative of deep  vein  thrombosis / pulmonary embolism.
Superficial  thrombophlebitis.